Announcements
- Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
- Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
- Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
- Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
- Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
More ▼
Key statistics
As of last trade, Purple Biotech Ltd (1YI1:MUN) traded at 0.362, 10.37% above the 52 week low of 0.328 set on Jul 10, 2024.
52-week range
Open | 0.362 |
---|---|
High | 0.362 |
Low | 0.362 |
Bid | 0.338 |
Offer | 0.37 |
Previous close | 0.362 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.68m |
Free float | 27.91m |
P/E (TTM) | -- |
Market cap | 13.20m USD |
EPS (TTM) | -0.7402 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 07:04 BST.
More ▼